Javaid Huma, Marin Ivan, Montalvan Jessica, Healy Logan, Nagi Chandandeep, Menegaz Brian A, Bonefas Elizabeth, Carter Stacey A, Thompson Alastair M, Miah Pabel A
Departments of Surgery, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
Departments of Pathology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
Eur J Surg Oncol. 2025 Sep;51(9):110215. doi: 10.1016/j.ejso.2025.110215. Epub 2025 Jun 6.
Cancer free margins from breast conservation surgery (BCS) are essential to avoid re-excision procedures, minimize risk of local recurrence, and for adjuvant therapy without delay. Approximately 20-25 % of patients who undergo BCS require additional procedures to remove residual disease, suggesting an ongoing need for effective intraoperative margin assessment. Intraoperative pathology assessment by frozen sections and cytology yields high diagnostic accuracy, but is time-consuming, resource-intensive, and evaluates limited sampling points. Alternative technologies provide more rapid results but are limited by relatively low sensitivity. Technologies in development show promise for diagnostic accuracy but remain to be proven in clinical practice. The objective of this study is to provide a comprehensive summary of current margin assessment methods for surgeons to utilize in the intraoperative setting.
This study reviewed scientific literature from January 2009 to December 2022 consisting of 40 manuscripts of current and proposed intraoperative margin assessment techniques for BCS from PubMed and Google Scholar. Overall, eight current technologies and ten technologies under development were evaluated based on the type of technology employed.
Pathologic evaluation with cytology had the highest sensitivity and specificity with 97 % and 99 % respectively. Technologies utilizing bioimpedance spectroscopy had sensitivities ranging from 13 % to 87 %. Mass spectrometry devices had sensitivities ranging from 80 % to 100 % and specificities ranging from 84 % to 98.85 %. Other technologies including optical coherence tomography, pharmacology, and X-ray combined technologies had sensitivities of 93 %-96 %, 49.3 %-98 %, and 56 %-85.6 % respectively.
The effectiveness in lowering re-excision rates derived from their respective advantages, limitations, sensitivity, and specificity were reviewed and have yet to replace pathologic assessment. Appropriate and effective intraoperative margin assessment would lower final positive margins and subsequent re-excision rates in BCS. Surgeons should utilize technology based on availability and experience.
保乳手术(BCS)切缘阴性对于避免再次切除手术、将局部复发风险降至最低以及及时进行辅助治疗至关重要。接受保乳手术的患者中,约20%-25%需要额外手术以清除残留病灶,这表明持续需要有效的术中切缘评估。通过冰冻切片和细胞学进行术中病理评估具有较高的诊断准确性,但耗时、资源密集且评估的采样点有限。替代技术能提供更快的结果,但受相对较低的灵敏度限制。正在研发的技术在诊断准确性方面显示出前景,但仍有待在临床实践中得到验证。本研究的目的是为外科医生在术中提供当前切缘评估方法的全面总结。
本研究回顾了2009年1月至2022年12月的科学文献,包括来自PubMed和谷歌学术的40篇关于当前及提议的保乳手术术中切缘评估技术的手稿。总体而言,根据所采用的技术类型对8种现有技术和10种正在研发的技术进行了评估。
细胞学病理评估的灵敏度和特异性最高,分别为97%和99%。利用生物电阻抗光谱法的技术灵敏度范围为13%至87%。质谱设备的灵敏度范围为80%至100%,特异性范围为84%至98.85%。其他技术,包括光学相干断层扫描、药理学和X射线联合技术,灵敏度分别为93%-96%、49.3%-98%和56%-85.6%。
回顾了各种技术在降低再次切除率方面的有效性,这些技术各有优缺点、灵敏度和特异性,尚未取代病理评估。适当有效的术中切缘评估将降低保乳手术最终的阳性切缘率和后续再次切除率。外科医生应根据可获得性和经验来使用技术。